EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of Mavacamten

Louis Lebreton iD, Jean-Christophe Boyer, Claire Lafay-Chebassier iD, Benjamin Hennart iD, Sarah Baklouti, Séverine Cunat iD, Paul Vilquin, Yves Medard, Elodie Gautier-Veyret iD, Clara Laffitte-Redondo iD, Céline Verstuyft iD, Abd El Kader Ait Tayeb iD und 10 weitere

Clinical Pharmacology & Therapeutics · 2025-02 · 117 (2) · 387-397

DOI: 10.1002/cpt.3502 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 25.11.2024. Verfasst von Louis Lebreton und 21 weiteren Autor:innen. Beteiligte Einrichtung: Département de Biochimie, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Pharmacogenetics, Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mavacamten, the first drug in the class of β‐cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 poor metabolizers have increased exposure and are at increased risk of reduced cardiac hypercontractility. To ensure the safety of all patients, European Medicines Agency recommends CYP2C19 preemptive genotyping, and consecutively, to adapt maintenance and initial mavacamten doses, and to manage drug–drug interactions, according to CYP2C19 phenotype. In this article, we summarize evidence from the literature supporting the association between CYP2C19 phenotype and pharmacological features of mavacamten and provide, beyond biologic guidelines, therapeutic recommendations for the use of mavacamten based on CYP2C19 and CYP3A4/CYP3A5 genotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19PharmacogeneticsCardiomyopathy, HypertrophicHumansDrug InteractionsPhenotypeGenotypeCytochrome P-450 CYP3APharmacogenomic Variants

Substanzen

Cytochrome P-450 CYP2C19CYP2C19 protein, humanCytochrome P-450 CYP3ACYP3A5 protein, human

Autor:innen und Institutionen

  • Département de Biochimie, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
  • Laboratoire de Biochimie et Biologie Moléculaire, Carémeau University Hospital, Nîmes, France.
  • Service de Pharmacologie Clinique et Vigilances, CHU Poitiers, Poitiers, France.
  • Unité Fonctionnelle de Toxicologie, CHU de Lille, Lille, France.
  • Laboratoire de Pharmacocinétique et Toxicologie, Institut Fédératif de Biologie, CHU de Toulouse, Toulouse, France.
  • INTHERES, Inrae, ENVT, Université de Toulouse, Toulouse, France.

ORCID-Profile: Louis Lebreton, Claire Lafay-Chebassier, Benjamin Hennart, Séverine Cunat, Elodie Gautier-Veyret, Clara Laffitte-Redondo, Céline Verstuyft, Abd El Kader Ait Tayeb, Vincent Haufroid, Julien Wils, Nicolas Picard, Estelle Ayme-Dietrich

Zitieren

APA

Lebreton, L., Boyer, J. C., Lafay-Chebassier, C., Hennart, B., Baklouti, S., Cunat, S., Vilquin, P., Medard, Y., Gautier-Veyret, E., Laffitte-Redondo, C., Verstuyft, C., Ait Tayeb, A. E. K., Haufroid, V., Wils, J., Lamoureux, F., Evrard, A., Davaze-Schneider, J., Ben-Sassi, M., Picard, N., …, & French‐Speaking Network of Pharmacogenetics (RNPGx) (2025). French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of Mavacamten. Clinical Pharmacology & Therapeutics, 117(2), 387-397. https://doi.org/10.1002/cpt.3502

Vancouver

Lebreton L, Boyer JC, Lafay-Chebassier C, Hennart B, Baklouti S, Cunat S, et al. French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of Mavacamten. Clinical Pharmacology & Therapeutics. 2025;117(2):387-397. doi:10.1002/cpt.3502

BibTeX
@article{Lebreton2025,
  author = {Lebreton, Louis and Boyer, Jean-Christophe and Lafay-Chebassier, Claire and Hennart, Benjamin and Baklouti, Sarah and Cunat, Séverine and Vilquin, Paul and Medard, Yves and Gautier-Veyret, Elodie and Laffitte-Redondo, Clara and Verstuyft, Céline and Ait Tayeb, Abd El Kader and Haufroid, Vincent and Wils, Julien and Lamoureux, Fabien and Evrard, Alexandre and Davaze-Schneider, Julie and Ben-Sassi, Mouna and Picard, Nicolas and Quaranta, Sylvie and Ayme-Dietrich, Estelle and French‐Speaking Network of Pharmacogenetics (RNPGx), French‐Speaking Network of Pharmacogenetics (RNPGx)},
  title = {French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of Mavacamten},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {2},
  pages = {387--397},
  doi = {10.1002/cpt.3502}
}
Kostenlos starten →